NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News $11.81 -0.81 (-6.42%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$11.77▼$12.6150-Day Range$11.81▼$19.8252-Week Range$11.56▼$62.06Volume559,427 shsAverage Volume266,969 shsMarket Capitalization$248.72 millionP/E RatioN/ADividend YieldN/APrice Target$38.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside226.0% Upside$38.50 Price TargetShort InterestBearish8.62% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.29Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($7.24) to ($7.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector194th out of 961 stocksPharmaceutical Preparations Industry79th out of 448 stocks 4.1 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.50, Enanta Pharmaceuticals has a forecasted upside of 226.0% from its current price of $11.81.Amount of Analyst CoverageEnanta Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.62% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 16.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 2.9 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for ENTA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.70% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($7.24) to ($7.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enanta Pharmaceuticals (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Given Buy Rating at HC WainwrightSeptember 19, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Enanta PharmaSeptember 21, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 17, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza ConferenceSeptember 12, 2023 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to Hold at StockNews.comSeptember 7, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023August 13, 2023 | finance.yahoo.comThings Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's DowngradeAugust 9, 2023 | msn.comJP Morgan cuts Enanta to neutral, cites extended timelines for key drugsSeptember 21, 2023 | Stansberry Research (Ad)Is NVIDIA Leading a "Magnificent Seven Bubble"?The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. August 9, 2023 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Call TranscriptAugust 9, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Enanta Pharmaceuticals (ENTA)August 8, 2023 | msn.comJefferies cuts Enanta to hold, cites concerns about COVID-19 drugAugust 8, 2023 | markets.businessinsider.comJefferies downgrades Enanta Pharmaceuticals (ENTA) to a HoldAugust 8, 2023 | finance.yahoo.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ETAugust 8, 2023 | finance.yahoo.comEnanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue EstimatesAugust 4, 2023 | benzinga.comEnanta Pharma's Earnings: A PreviewJuly 31, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023June 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Enanta Pharmaceuticals (ENTA)June 21, 2023 | finance.yahoo.comAre Options Traders Betting on a Big Move in Enanta Pharmaceuticals (ENTA) Stock?June 20, 2023 | finance.yahoo.comEnanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial VirusJune 7, 2023 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023May 31, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Participate at Jefferies Global Healthcare ConferenceMay 12, 2023 | msn.comOppenheimer Reiterates Enanta Pharmaceuticals (ENTA) Perform RecommendationMay 11, 2023 | msn.comEnanta Pharma GAAP EPS of -$1.79 beats by $0.45, revenue of $17.8M beats by $4.91MMay 11, 2023 | seekingalpha.comEnanta Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 11, 2023 | msn.comJMP Securities Maintains Enanta Pharmaceuticals (ENTA) Outperform RecommendationMay 9, 2023 | markets.businessinsider.comWhy Enanta Shares Are Plunging TodaySee More Headlines Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Company Calendar Last Earnings8/07/2023Today9/21/2023Fiscal Year End9/30/2023Next Earnings (Estimated)11/20/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees160Year FoundedN/APrice Target and Rating Average Stock Price Forecast$38.50 High Stock Price Forecast$87.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+205.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($6.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-121,750,000.00 Net Margins-163.87% Pretax Margin-158.55% Return on Equity-46.77% Return on Assets-34.20% Debt Debt-to-Equity RatioN/A Current Ratio6.58 Quick Ratio6.58 Sales & Book Value Annual Sales$86.16 million Price / Sales3.08 Cash FlowN/A Price / Cash FlowN/A Book Value$15.51 per share Price / Book0.81Miscellaneous Outstanding Shares21,060,000Free Float18,381,000Market Cap$265.78 million OptionableOptionable Beta0.41 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Jay R. Luly Ph.D. (Age 67)Pres, CEO & Director Comp: $1.23MMr. Paul J. Mellett Jr. (Age 68)Sr. VP of Fin. & Admin. and CFO Comp: $650.94kDr. Yat Sun Or Ph.D. (Age 71)Sr. VP of R&D and Chief Scientific Officer Comp: $720.16kMr. Nathaniel S. Gardiner J.D. (Age 69)Sr. VP, Gen. Counsel & Sec. Comp: $657.95kDr. Scott T. Rottinghaus M.D. (Age 49)Sr. VP & Chief Medical Officer Comp: $616.73kMs. Jennifer VieraSr. Director of Investor Relations & Corp. CommunicationsDr. Nathalie Adda M.D. (Age 57)Consultant Ms. Tara Lynn Kieffer Ph.D. (Age 45)Sr. VP of New Product Strategy & Devel. Mr. Brendan Luu (Age 48)Sr. VP of Bus. Devel. More ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULAtea PharmaceuticalsNASDAQ:AVIROvid TherapeuticsNASDAQ:OVIDInozyme PharmaNASDAQ:INZYGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsComerica BankBought 785 shares on 8/22/2023Ownership: 0.004%California State Teachers Retirement SystemSold 658 shares on 8/21/2023Ownership: 0.114%Alliancebernstein L.P.Bought 2,670 shares on 8/15/2023Ownership: 0.105%Royal Bank of CanadaBought 1,085 shares on 8/15/2023Ownership: 0.013%Citadel Advisors LLCSold 800 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ENTA Stock - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price forecast for 2023? 8 analysts have issued 1 year target prices for Enanta Pharmaceuticals' shares. Their ENTA share price forecasts range from $14.00 to $87.00. On average, they predict the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 205.1% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2023? Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of the year. Since then, ENTA stock has decreased by 72.9% and is now trading at $12.62. View the best growth stocks for 2023 here. Are investors shorting Enanta Pharmaceuticals? Enanta Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,680,000 shares, an increase of 16.7% from the August 15th total of 1,440,000 shares. Based on an average daily trading volume, of 278,600 shares, the days-to-cover ratio is currently 6.0 days. Approximately 8.6% of the shares of the company are short sold. View Enanta Pharmaceuticals' Short Interest. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023. View our ENTA earnings forecast. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.38) by $0.52. The biotechnology company earned $18.89 million during the quarter, compared to the consensus estimate of $15.88 million. Enanta Pharmaceuticals had a negative net margin of 163.87% and a negative trailing twelve-month return on equity of 46.77%. What ETF holds Enanta Pharmaceuticals' stock ? ETFMG Treatments Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio. What guidance has Enanta Pharmaceuticals issued on next quarter's earnings? Enanta Pharmaceuticals updated its third quarter earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of ($1.86) for the period, compared to the consensus earnings per share estimate of ($2.25). The company issued revenue guidance of $18.9 million, compared to the consensus revenue estimate of $18.19 million. What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.71%), State Street Corp (7.21%), Northern Trust Corp (4.63%), Krensavage Asset Management LLC (3.27%), Renaissance Technologies LLC (2.26%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $12.62. How much money does Enanta Pharmaceuticals make? Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $265.78 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($6.31) on an earnings per share basis. How many employees does Enanta Pharmaceuticals have? The company employs 160 workers across the globe. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530. This page (NASDAQ:ENTA) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.